SOLICITATION NOTICE
66 -- Purchase of a MesoQuick Plex SQ 120
- Notice Date
- 4/16/2014
- Notice Type
- Presolicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02CP42518-63
- Archive Date
- 5/3/2014
- Point of Contact
- Seena Ninan, Phone: 240-276-5419
- E-Mail Address
-
ninans@mail.nih.gov
(ninans@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Laboratory of Translational Genetics, plans to procure on a sole source basis the purchase of the MesoQuick Plex SQ 120 from Meso Scale Discovery, 1601 Research Blvd, Rockville MD 20850. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). The North American Industry Classification System code is 334516 and the business size standard is 500 employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. It has been determined there are no opportunities to acquire green products or services for this procurement. Delivery Date: 60 days from date of award. The laboratory of Translational Genetics recently identified a new genetic variant in the IFNL3 region that has a stronger association with hepatitis C virus (HCV) infection clearance than a previously used genetic marker, rs12979860, in both European and African American subjects. This new marker, IFNL4, would be a better test for hepatitis C patients in determining their ability to clear the virus. This is important in the treatment of this disease, especially among patients of African ancestry. This discovery has led to continuing efforts to examine the functional role of IFNL4 in a variety of infectious human diseases. However, there are no methods available to quantitatively detect IFNL4 protein levels in human samples. NCI has developed a pair of two monoclonal antibodies, specific to two different regions of IFNL4; mouse and rabbit monoclonals. There is currently a working enzyme linked immunosorbent assay (ELISA), but it is not sensitive enough to detect IFNL4 in the patient samples. To further investigate the ability to detect IFNL4 protein, NCI plans to examine technologies that are proven to be considerably more sensitive than the current ELISA; electrochemiluminescence (ECL). ECL, generated using Ruthenium chelates, allows light emission to be used to detect low concentrations of proteins. Progressive development of this technology has led to the detection of atto-molar concentrations of some proteins, thereby enabling unprecedented levels of sensitivity in analyzing the content of biological samples. Conventional biochemical detection methods such as immunoblotting or ELISA are not comparable. While mass spectrometry offers similar levels of sensitivity, it is not high throughput, not easily adapted to complex biological samples, and uses far more costly instrumentation. The MesoQuick Plex SQ120 is a multiplexing instrument that does high-performance electrochemiluminescence (ECL) immunoassays. Being able to detect levels of INFL4 in patient blood samples is extremely beneficial to NCI, collaborators within the NIH, and to other investigators, because it allows stakeholders to quantitatively determine whether treatment regimens for HCV are effective. In addition, it has allowed to experimentally determining how IFNL4 is being released from the cell, and addressing other functional aspects of INFL4 in HCV disease, as well as other infectious diseases. The Meso QuickPlex SQ120 electrochemiluminescence analytical instruments are manufactured and sold soley by Meso Scale Discovery (MSD), a division of Meso Scale Diagnostics, LLC, of Gaithersburg, MD. The imager is compatible only with microwell plates and immunoassays kits sold by MSD. MSD utilizes electrochemiluminescence to detect binding events on patterned arrays. There are no other known technologies that enable multiplexed measurement using electrochemiluminescence for detection as well as no other known suppliers that provide an electrochemiluminescence detection system that is not reliant on beads or flow cells. The MSD platform is unique in its method for detection as outlined below: • Electrochemiluminescence (ECL) Detection - MSD's ECL detection utilizes proprietary SULFO-TAG labels that emit light upon electrochemical stimulation initiated at the electrode surfaces of MULTI-ARRAY® and MULTI-SPOT® microplates through biomolecular interactions between the analyte and labeled reporter at the surface. • Sample Throughput - The Meso QuickPlex SQ 120 Imager instruments can read plates in 1 to 3.5 minutes regardless of the multiplexing level. • Non-fluidic, high-reliability instruments - All assay processing and readout steps take place in MSD's disposable plate-based format. No sample is transferred from the plate to the instrument and hence there are no complicated fluidics that may be prone to clogging and other failures. MSD's instrumentation has been highly praised by customers for exceptional reliability. • Sample Savings - Only 25 ul of sample. Other platforms require 2-4 times this requirement. • Wide dynamic range - ECL has a dynamic range that can be two-fold over absorbence or fluorescent assays. • Higher sensitivity - Sensitivity is defined as signal divided by background. This system provides a higher signal and lower background over the ELISA. • Efficient workflow - This allows more screening of more samples in less time. • No wash assays - Excessive washing, as is required in a normal ELISA, can wash away sample proteins. This notice is not a request for competitive quotation. However, if any interested party, especially small business believes it can meet the above requirement, it may submit a proposal or quote for the Government to consider. The response and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 11 AM EST, on May 2, 2014. All responses and questions must be in writing and faxed to 240-276-5399 or emailed to Seena Ninan, Contracting Specialist via electronic mail at seena.ninan@nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA) through sam.gov. Reference: N02CP42518-63 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02CP42518-63 /listing.html)
- Record
- SN03340224-W 20140418/140416234903-58e9d627ded3e203450d5eedfcb97262 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |